Frank C. Odds
University of Aberdeen
289 Papers
4.3K Citations
Frank C. Odds is an academic researcher from University of Aberdeen. The author has contributed to research in topics: Candida albicans & Corpus albicans. The author has an hindex of 82, co-authored 289 publications. Previous affiliations of Frank C. Odds include University of Cincinnati Academic Health Center & Janssen Pharmaceutica.
Chat about Author
Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Ben E. De Pauw,Thomas J. Walsh,J. Peter Donnelly,David A. Stevens,John E. Edwards,Thierry Calandra,Peter G. Pappas,Johan Maertens,Olivier Lortholary,Carol A. Kauffman,David W. Denning,Thomas F. Patterson,Georg Maschmeyer,Jacques Bille,William E. Dismukes,Raoul Herbrecht,William W. Hope,Christopher C. Kibbler,Bart Jan Kullberg,Kieren A. Marr,Patricia Muñoz,Frank C. Odds,John R. Perfect,Angela Restrepo,Markus Ruhnke,Brahm H. Segal,Jack D. Sobel,Tania C. Sorrell,Claudio Viscoli,John R. Wingard,Theoklis E. Zaoutis,John E. Bennett +31 more
TL;DR: These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.
4.9K
Synergy, antagonism, and what the chequerboard puts between them
TL;DR: This document is intended to be used for educational purposes only and should not be relied on as a guide for making decisions about major decisions about copyrighted material.
Antifungal agents: mechanisms of action
TL;DR: The sordarins represent a novel class of agents that inhibit fungal protein synthesis, and three are echinocandins, which inhibit synthesis of fungal cell wall polysaccharides--a new mode of action.
1.2K
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
John H. Rex,Michael A. Pfaller,John N. Galgiani,Marilyn S. Bartlett,Ana Espinel-Ingroff,Mahmoud A. Ghannoum,M Lancaster,Frank C. Odds,Michael G. Rinaldi,Thomas J. Walsh,A L Barry +10 more
TL;DR: The conceptual framework underlying interpretation of antimicrobial susceptibility testing results is examined and these ideas are used to drive analysis of data packages developed by the respective manufacturers that correlate fluconazole and itraconazole MICs with outcome of candidal infections.
855
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Dominique Sanglard,Frank C. Odds +1 more
TL;DR: Recent large-scale surveys of yeasts isolated from blood cultures, based on standardised methodology and resistance definitions, do not support the view that antifungal resistance in pathogenic yeasts constitutes a significant or growing therapeutic problem.
817